Cargando…

Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution

PURPOSE: Glucocorticoids are widely used medications. In many pharmacoepidemiological studies, duration of individual prescriptions and definition of treatment episodes are important issues. However, many data sources lack this information. We aimed to estimate duration of individual prescriptions f...

Descripción completa

Detalles Bibliográficos
Autores principales: Laugesen, Kristina, Støvring, Henrik, Hallas, Jesper, Pottegård, Anton, Jørgensen, Jens Otto Lunde, Sørensen, Henrik Toft, Petersen, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697451/
https://www.ncbi.nlm.nih.gov/pubmed/29180903
http://dx.doi.org/10.2147/CLEP.S148671
_version_ 1783280624832872448
author Laugesen, Kristina
Støvring, Henrik
Hallas, Jesper
Pottegård, Anton
Jørgensen, Jens Otto Lunde
Sørensen, Henrik Toft
Petersen, Irene
author_facet Laugesen, Kristina
Støvring, Henrik
Hallas, Jesper
Pottegård, Anton
Jørgensen, Jens Otto Lunde
Sørensen, Henrik Toft
Petersen, Irene
author_sort Laugesen, Kristina
collection PubMed
description PURPOSE: Glucocorticoids are widely used medications. In many pharmacoepidemiological studies, duration of individual prescriptions and definition of treatment episodes are important issues. However, many data sources lack this information. We aimed to estimate duration of individual prescriptions for oral glucocorticoids and to describe continuous treatment episodes using the parametric waiting time distribution. METHODS: We used Danish nationwide registries to identify all prescriptions for oral glucocorticoids during 1996–2014. We applied the parametric waiting time distribution to estimate duration of individual prescriptions each year by estimating the 80th, 90th, 95th and 99th percentiles for the interarrival distribution. These corresponded to the time since last prescription during which 80%, 90%, 95% and 99% of users presented a new prescription for redemption. We used the Kaplan–Meier survival function to estimate length of first continuous treatment episodes by assigning estimated prescription duration to each prescription and thereby create treatment episodes from overlapping prescriptions. RESULTS: We identified 5,691,985 prescriptions issued to 854,429 individuals of whom 351,202 (41%) only redeemed 1 prescription in the whole study period. The 80th percentile for prescription duration ranged from 87 to 120 days, the 90th percentile from 116 to 150 days, the 95th percentile from 147 to 181 days, and the 99th percentile from 228 to 259 days during 1996–2014. Based on the 80th, 90th, 95th and 99th percentiles of prescription duration, the median length of continuous treatment was 113, 141, 170 and 243 days, respectively. CONCLUSION: Our method and results may provide an important framework for future pharmacoepidemiological studies. The choice of which percentile of the interarrival distribution to apply as prescription duration has an impact on the level of misclassification. Use of the 80th percentile provides a measure of drug exposure that is specific, while the 99th percentile provides a sensitive measure.
format Online
Article
Text
id pubmed-5697451
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56974512017-11-27 Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution Laugesen, Kristina Støvring, Henrik Hallas, Jesper Pottegård, Anton Jørgensen, Jens Otto Lunde Sørensen, Henrik Toft Petersen, Irene Clin Epidemiol Original Research PURPOSE: Glucocorticoids are widely used medications. In many pharmacoepidemiological studies, duration of individual prescriptions and definition of treatment episodes are important issues. However, many data sources lack this information. We aimed to estimate duration of individual prescriptions for oral glucocorticoids and to describe continuous treatment episodes using the parametric waiting time distribution. METHODS: We used Danish nationwide registries to identify all prescriptions for oral glucocorticoids during 1996–2014. We applied the parametric waiting time distribution to estimate duration of individual prescriptions each year by estimating the 80th, 90th, 95th and 99th percentiles for the interarrival distribution. These corresponded to the time since last prescription during which 80%, 90%, 95% and 99% of users presented a new prescription for redemption. We used the Kaplan–Meier survival function to estimate length of first continuous treatment episodes by assigning estimated prescription duration to each prescription and thereby create treatment episodes from overlapping prescriptions. RESULTS: We identified 5,691,985 prescriptions issued to 854,429 individuals of whom 351,202 (41%) only redeemed 1 prescription in the whole study period. The 80th percentile for prescription duration ranged from 87 to 120 days, the 90th percentile from 116 to 150 days, the 95th percentile from 147 to 181 days, and the 99th percentile from 228 to 259 days during 1996–2014. Based on the 80th, 90th, 95th and 99th percentiles of prescription duration, the median length of continuous treatment was 113, 141, 170 and 243 days, respectively. CONCLUSION: Our method and results may provide an important framework for future pharmacoepidemiological studies. The choice of which percentile of the interarrival distribution to apply as prescription duration has an impact on the level of misclassification. Use of the 80th percentile provides a measure of drug exposure that is specific, while the 99th percentile provides a sensitive measure. Dove Medical Press 2017-11-16 /pmc/articles/PMC5697451/ /pubmed/29180903 http://dx.doi.org/10.2147/CLEP.S148671 Text en © 2017 Laugesen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Laugesen, Kristina
Støvring, Henrik
Hallas, Jesper
Pottegård, Anton
Jørgensen, Jens Otto Lunde
Sørensen, Henrik Toft
Petersen, Irene
Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
title Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
title_full Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
title_fullStr Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
title_full_unstemmed Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
title_short Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
title_sort prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697451/
https://www.ncbi.nlm.nih.gov/pubmed/29180903
http://dx.doi.org/10.2147/CLEP.S148671
work_keys_str_mv AT laugesenkristina prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution
AT støvringhenrik prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution
AT hallasjesper prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution
AT pottegardanton prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution
AT jørgensenjensottolunde prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution
AT sørensenhenriktoft prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution
AT petersenirene prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution